Celsion Bolsters Clinical Development Team.COLUMBIA, Md. -- CELSION CORPORATION (AMEX AMEX See: American Stock Exchange : CLN CLN Clean CLN Community Learning Network CLN Colon CLN Celsion Corporation CLN Class Library for Numbers CLN Credit Linked Note CLN Comitato di Liberazione Nazionale (Committee of National Liberation) CLN Corn Lethal Necrosis ) today announced the appointment, effective October 1, 2007, of Nicholas Borys, M.D. to the position of Vice President and Chief Medical Officer. In this position Dr. Borys will manage the clinical development program for Celsion. Dr. Borys, who was most recently Chief Medical Officer at Molecular Insight Pharmaceuticals, Inc., has accumulated extensive experience in oncology and all phases of pharmaceutical development while holding increasingly senior positions at Taiho Pharma USA, Cytogen Corporation, Anthra Pharmaceuticals, Inc., Amersham Healthcare, Inc. and Hoffmann La-Roche Inc. Dr. William Hahne, Celsion's Vice President, Clinical and Medical Affairs will collaborate with Dr. Borys on developing Celsion's clinical strategy for its current primary liver cancer Liver Cancer Definition Liver cancer is a relatively rare form of cancer but has a high mortality rate. Liver cancers can be classified into two types. and recurrent breast cancer at the chest wall pivotal programs. In addition, they will explore and identify additional indications for ThermoDox([R]), the company's proprietary heat activated liposomal formulation of doxorubicin doxorubicin /doxo·ru·bi·cin/ (dok?so-roo´bi-sin) an antineoplastic antibiotic, produced by Streptomyces peucetius, which binds to DNA and inhibits nucleic acid synthesis; used as the hydrochloride salt and as a liposome-encased , as well as other chemotherapeutic drugs, based on the company's unique heat activated liposome liposome (lī`pəsōm', lĭp`ə–), microscopic, fluid-filled pouch whose walls are made of layers of phospholipids identical to the phospholipids that make up cell membranes. platform technology. Michael H. Tardugno, Celsion's President and Chief Executive Officer commented, "We are delighted that Dr. Borys has joined our team. Dr. Borys has a wealth of clinical development experience with a strong focus on oncology, and will be very valuable to the company as it initiates its primary liver cancer pivotal study, and develops plans to advance the recurrent breast cancer at the chest wall program to a pivotal study." Mr. Tardugno added, "Dr. Borys' addition is in line with our focus of building an organization with the clinical and scientific competencies to execute our strategy. Both Dr. Hahne and Dr. Borys have extensive experience in the oncology arena. The product of their collective strength and experience should prove to be a very valuable asset for Celsion." About Celsion: Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong The University of Hong Kong (commonly abbreviated as HKU, pronounced as "Hong Kong U") is the oldest tertiary institution in Hong Kong. Its motto is "Sapientia et Virtus" in Latin, and " , Cleveland Clinic Cleveland Clinic (formally known as the Cleveland Clinic Foundation) is a multispecialty academic medical center located in Cleveland, Ohio, USA. Cleveland Clinic was established in 1921 by four physicians for the purpose of providing patient care, research, and medical , North Shore Long Island Jewish Health System. Additional information about Celsion Corporation can be found on the Celsion web site at www.celsion.com. Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion